Campaigning to keep vital drug on Cancer Drugs Fund
This week, NHS England have been reviewing whether the chemotherapy drug Abraxane should remain on the Cancer Drugs Fund (CDF) in England. Currently, the combination of gemcitabine and Abraxane is routinely available on the NHS in Scotland and Wales but patients in England (who make up 83% of all pancreatic cancer patients) are only able to access the drug by applying to the CDF. If Abraxane is taken off the CDF, then patients in England will only be able to access it privately. This is an unacceptable situation and why we have spent this week raising this issue in the media.
On Tuesday, Pancreatic Cancer Action CEO and Founder (and nearly 8 year survivor of pancreatic cancer) along with Penny Lown (pancreatic cancer survivor and one of the faces of last year’s advertising campaign) and Broadcast Medic and GP, Dr Hilary Jones gave over 20 radio interviews across England.
On Wednesday morning, Ali Stunt and Penny Lown gave an interview on Sky News Sunrise programme which you can view here: